Last Update 09 Apr 26
ATT: Proposed 2025 Dividend And Governance Changes Will Support Steady Outlook
Analysts have kept Attendo's fair value estimate unchanged at SEK110, with only minor tweaks to inputs such as the discount rate and future P/E assumptions guiding this level view.
What's in the News
- The Board has proposed an amendment to Attendo AB (publ)'s Articles of Association, signaling upcoming changes to the company's formal governance framework (Key Developments).
- The Board of Directors plans to ask the 2026 Annual General Meeting to approve a dividend of SEK 1.80 per share for 2025, with the payment split into two installments (Key Developments).
- The proposed record dates for the dividend are 8 May 2026 and 10 November 2026, with expected payment dates of 13 May 2026 and 13 November 2026 if approved (Key Developments).
- Attendo intends to hold an analyst and investor event to discuss updated financial targets announced with the year-end report on 5 February 2026 and to provide a general update on the company's 2026 to 2028 plan (Key Developments).
Valuation Changes
- Fair Value: Kept unchanged at SEK110.0 per share, indicating no revision to the overall valuation level.
- Discount Rate: Reduced slightly from 5.80% to 5.68%, a small adjustment to the rate used to discount future cash flows.
- Revenue Growth: Maintained effectively flat at about 2.83%, with only a negligible numerical refinement.
- Net Profit Margin: Held steady at roughly 5.34%, with the update reflecting a minor rounding adjustment rather than a directional change.
- Future P/E: Trimmed slightly from 15.83x to 15.77x, indicating a very small change in the valuation multiple applied to future earnings.
Key Takeaways
- Accelerated capacity expansion, regulatory tailwinds, and strong brand positioning are driving sustained revenue growth, market share gains, and higher contract win rates.
- Ongoing efficiency initiatives and increased financial flexibility are supporting margin improvements, strategic investments, and stable long-term earnings.
- Contract exits and regulatory shifts are driving revenue pressure, margin volatility, and uncertainty about long-term growth and profitability, despite some operational improvements.
Catalysts
About Attendo- Provides health and care services in Scandinavia and Finland.
- Accelerating capacity expansion through new care home openings and targeted acquisitions is positioning Attendo to benefit from increasing elderly care demand driven by demographic shifts in Scandinavia and Finland, supporting sustained revenue and occupancy growth.
- Positive regulatory changes in Finland-such as the relaxation of mandatory municipal capacity usage after a 3-year transition and ongoing demand queue build-up-are likely to boost market share for private providers like Attendo, enhancing long-term revenue visibility and growth.
- Operational efficiency initiatives, including better staffing systems, digitalization projects, and AI pilots, are already driving significant margin improvements, and continued efficiency gains are expected to further boost net margins and earnings.
- Improved customer satisfaction, with cNPS at an all-time high, coupled with strong brand positioning and expertise, strengthens Attendo's competitive advantage in public tenders, likely contributing to higher contract win rates and stable revenue streams.
- Increased financial flexibility-backed by strong free cash flow, active capital allocation (dividends and share buybacks), and an expanded revolving credit facility-enables Attendo to reinvest in bolt-on acquisitions and strategic growth projects, supporting both top-line and bottom-line improvement.
Attendo Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Attendo's revenue will grow by 2.8% annually over the next 3 years.
- Analysts assume that profit margins will increase from 4.3% today to 5.3% in 3 years time.
- Analysts expect earnings to reach SEK 1.1 billion (and earnings per share of SEK 8.18) by about April 2029, up from SEK 813.0 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.8x on those 2029 earnings, down from 18.8x today. This future PE is lower than the current PE for the GB Healthcare industry at 18.6x.
- Analysts expect the number of shares outstanding to decline by 2.68% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 5.68%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Ongoing termination of home care and outsourcing contracts due to unsustainable terms in Scandinavia is resulting in immediate non-recurring costs, reduced volumes, and flat or declining reported sales growth, particularly impacting revenue and net margins as this business line is rationalized.
- Top-line sales have been negatively affected by currency headwinds (weaker euro), ended contracts, and lower pricing in segments such as Finnish Elderly Care due to regulatory changes (lower staffing requirements), highlighting exposure to both FX risk and governmental policy shifts, which can further depress revenue and earnings.
- Home care segment faces operational challenges and profitability issues, evidenced by contract exits, ramp-down inefficiencies (staff costs without matching revenue), and a need for ongoing structural changes, all leading to margin pressure and volatility in short
- to mid-term earnings.
- Future growth in Finland, while underpinned by demographic demand, depends in part on municipal regions' willingness and financial ability to shift more elderly care to private providers; if political momentum stalls or public skepticism grows against privatized care, revenue growth potential could be curtailed long term.
- Despite current operational improvements and cost savings from lower staffing requirements in Finland, sustained labor shortages, wage inflation, or future tightening of regulatory/quality mandates (such as increasing minimum staffing levels) may reverse margin gains and heighten cost pressures, directly impacting net margins and long-term earnings stability.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of SEK110.0 for Attendo based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK20.6 billion, earnings will come to SEK1.1 billion, and it would be trading on a PE ratio of 15.8x, assuming you use a discount rate of 5.7%.
- Given the current share price of SEK105.8, the analyst price target of SEK110.0 is 3.8% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Attendo?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

